Literature DB >> 21951660

Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Mi Li1, Alla Gustchina, Krisztina Matúz, Jozsef Tözsér, Sirilak Namwong, Nathan E Goldfarb, Ben M Dunn, Alexander Wlodawer.   

Abstract

Interactions between the protease (PR) encoded by the xenotropic murine leukemia virus-related virus and a number of potential inhibitors have been investigated by biochemical and structural techniques. It was observed that several inhibitors used clinically against HIV PR exhibit nanomolar or even subnanomolar values of K(i) , depending on the exact experimental conditions. Both TL-3, a universal inhibitor of retroviral PRs, and some inhibitors originally shown to inhibit plasmepsins were also quite potent, whereas inhibition by pepstatin A was considerably weaker. Crystal structures of the complexes of xenotropic murine leukemia virus-related virus PR with TL-3, amprenavir and pepstatin A were solved at high resolution and compared with the structures of complexes of these inhibitors with other retropepsins. Whereas TL-3 and amprenavir bound in a predictable manner, spanning the substrate-binding site of the enzyme, two molecules of pepstatin A bound simultaneously in an unprecedented manner, leaving the catalytic water molecule in place. Journal compilation
© 2011 FEBS. No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951660      PMCID: PMC3500906          DOI: 10.1111/j.1742-4658.2011.08364.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  47 in total

1.  Studies on the role of the S4 substrate binding site of HIV proteinases.

Authors:  J Tözsér; A Gustchina; I T Weber; I Blaha; E M Wondrak; S Oroszlan
Journal:  FEBS Lett       Date:  1991-02-25       Impact factor: 4.124

2.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

4.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.

Authors:  P M Fitzgerald; B M McKeever; J F VanMiddlesworth; J P Springer; J C Heimbach; C T Leu; W K Herber; R A Dixon; P L Darke
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

5.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

6.  Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.

Authors:  Anita Fehér; Péter Boross; Tamás Sperka; Gabriella Miklóssy; János Kádas; Péter Bagossi; Stephen Oroszlan; Irene T Weber; József Tözsér
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

Review 7.  Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.

Authors:  H B Fung; H L Kirschenbaum; R Hameed
Journal:  Clin Ther       Date:  2000-05       Impact factor: 3.393

8.  Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome.

Authors:  Harriet C T Groom; Virginie C Boucherit; Kerry Makinson; Edward Randal; Sarah Baptista; Suzanne Hagan; John W Gow; Frank M Mattes; Judith Breuer; Jonathan R Kerr; Jonathan P Stoye; Kate N Bishop
Journal:  Retrovirology       Date:  2010-02-15       Impact factor: 4.602

9.  Disease-associated XMRV sequences are consistent with laboratory contamination.

Authors:  Stéphane Hué; Eleanor R Gray; Astrid Gall; Aris Katzourakis; Choon Ping Tan; Charlotte J Houldcroft; Stuart McLaren; Deenan Pillay; Andrew Futreal; Jeremy A Garson; Oliver G Pybus; Paul Kellam; Greg J Towers
Journal:  Retrovirology       Date:  2010-12-20       Impact factor: 4.602

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Structure of RC1339/APRc from Rickettsia conorii, a retropepsin-like aspartic protease.

Authors:  Mi Li; Alla Gustchina; Rui Cruz; Marisa Simões; Pedro Curto; Juan Martinez; Carlos Faro; Isaura Simões; Alexander Wlodawer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2015-09-30

2.  Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Authors:  Krisztina Matúz; János Mótyán; Mi Li; Alexander Wlodawer; József Tőzsér
Journal:  FEBS J       Date:  2012-08-17       Impact factor: 5.542

3.  Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases.

Authors:  János András Mótyán; Márió Miczi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

4.  Biochemical characterization of Ty1 retrotransposon protease.

Authors:  Lívia Diána Gazda; Krisztina Joóné Matúz; Tibor Nagy; János András Mótyán; József Tőzsér
Journal:  PLoS One       Date:  2020-01-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.